Envestnet Portfolio Solutions Inc. Raises Holdings in Qiagen N.V. $QGEN

Envestnet Portfolio Solutions Inc. boosted its stake in shares of Qiagen N.V. (NYSE:QGEN) by 10.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,078 shares of the company’s stock after purchasing an additional 652 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Qiagen were worth $340,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in Qiagen during the 1st quarter worth about $31,000. Farther Finance Advisors LLC increased its holdings in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares during the period. Hilltop National Bank purchased a new stake in Qiagen during the 2nd quarter worth about $66,000. ANTIPODES PARTNERS Ltd purchased a new stake in Qiagen during the 1st quarter worth about $94,000. Finally, GAMMA Investing LLC increased its holdings in Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after purchasing an additional 1,425 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on QGEN. Cowen restated a “hold” rating on shares of Qiagen in a report on Thursday, August 7th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Qiagen in a report on Wednesday, October 8th. Barclays set a $53.00 price objective on Qiagen and gave the company an “overweight” rating in a report on Thursday, October 2nd. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, Bank of America increased their price objective on Qiagen from $50.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, June 26th. Three equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $49.69.

Qiagen Trading Up 1.6%

NYSE:QGEN opened at $49.39 on Friday. The stock’s 50 day moving average price is $47.00 and its 200 day moving average price is $46.02. The company has a market capitalization of $10.98 billion, a PE ratio of 29.18, a P/E/G ratio of 2.55 and a beta of 0.66. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 52-week low of $37.63 and a 52-week high of $51.88.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.